Clinical Outcomes With Definitive Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia With Retained Daptomycin and Ceftaroline Combination Therapy vs De-escalation to Monotherapy With Vancomycin, Daptomycin, or Ceftaroline

Nichols CN, Wardlow LC, Coe KE, Sobhanie MME. Clinical Outcomes with Definitive Treatment of Methicillin-Resistant *Staphylococcus aureus* Bacteremia with Retained Daptomycin and Ceftaroline Combination Therapy vs De-escalation to Monotherapy with Vancomycin, Daptomycin, or Ceftaroline. Open For Infect Dis. 2021:8(7):ofab327

Dr. Lynn Wardlow is an infectious diseases specialty practice pharmacist and residency program director for the PGY2 Infectious Diseases residency program at the Ohio State University Wexner Medical Center. She received her dual PharmD/MBA degree from Drake University in Des Moines, Iowa. Following graduation, she completed a PGY1 pharmacy residency at University of Arizona and PGY2 Infectious Diseases pharmacy residency at University of California–San Diego. She previously served as an infectious disease pharmacy specialist at University of Louisville Hospital where she initially became involved in SIDP prior to accepting her current position at the Ohio State in 2016. Her research interests include HIV, infections in immunocompromised hosts, global stewardship outreach, and optimizing transitions of care for patients on intravenous antimicrobials. Additionally, she serves as coordinator for Ohio State University College of Pharmacy student research at the medical center.

Dr. Wardlow conceived of the project, wrote the proposal and mentored an ID fellow through completion of the project. The impact of this project has a direct correlation to clinical care and antimicrobial stewardship, providing evidence against the use of continued combination therapy MRSA bacteremia once the bloodstream has cleared.